Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

被引：0

作者：

Giulia Bon

Laura Pizzuti

Valentina Laquintana

Rossella Loria

Manuela Porru

Caterina Marchiò

Eriseld Krasniqi

Maddalena Barba

Marcello Maugeri-Saccà

Teresa Gamucci

Rossana Berardi

Lorenzo Livi

Corrado Ficorella

Clara Natoli

Enrico Cortesi

Daniele Generali

Nicla La Verde

Alessandra Cassano

Emilio Bria

Luca Moscetti

Andrea Michelotti

Vincenzo Adamo

Claudio Zamagni

Giuseppe Tonini

Giacomo Barchiesi

Marco Mazzotta

Daniele Marinelli

Silverio Tomao

Paolo Marchetti

Maria Rosaria Valerio

Rosanna Mirabelli

Antonio Russo

Maria Agnese Fabbri

Nicola D’Ostilio

Enzo Veltri

Domenico Corsi

Ornella Garrone

Ida Paris

Giuseppina Sarobba

Francesco Giotta

Carlo Garufi

Marina Cazzaniga

Pietro Del Medico

Mario Roselli

Giuseppe Sanguineti

Isabella Sperduti

Anna Sapino

Ruggero De Maria

Carlo Leonetti

Angelo Di Leo

机构：

[1] IRCCS Regina Elena National Cancer Institute,Cellular Network and Molecular Therapeutic Target Unit

[2] IRCCS Regina Elena National Cancer Institute,Division of Medical Oncology 2

[3] IRCCS Regina Elena National CancerInstitute,Pathology Department

[4] IRCCS Regina Elena National Cancer Institute,Area of Translational Research

[5] University of Turin,Department of Medical Sciences

[6] Candiolo Cancer Institute,Medical Oncology

[7] FPO-IRCCS,Radiotherapy Unit, Department of Oncology

[8] Sandro Pertini Hospital,Medical Oncology Unit

[9] Oncology Clinic,Department of Medical, Oral and Biotechnological Sciences

[10] “Ospedali Riuniti di Ancona” Hospital,Department of Medical Oncology

[11] Careggi University Hospital,Oncology Unit, IRCCS Foundation Polyclinic University A. Gemelli

[12] St Salvatore Hospital,Department of Oncology and Hematology

[13] University Gabriele D’Annunzio,Medical Oncology Unit, A.O. Papardo & Department of Human Pathology

[14] University La Sapienza,Medical Oncology Unit, Addarii Institute of Oncology

[15] Breast Cancer Unit,Department of Oncology

[16] ASST Cremona,Medical Oncology Unit

[17] Oncology Unit,Department of Radiological, Oncological and Anatomo

[18] ASST Fatebenefratelli Sacco-PO Fatebenefratelli,Pathological Sciences

[19] University Cattolica Del Sacro Cuore,Medical Oncology

[20] University of Verona,Department of Ematology & Oncology

[21] University Hospital,Medical Oncology Unit

[22] UO Medical Oncology,Medical Oncology Unit

[23] S. Chiara Hospital,Gynaecology – Oncology Unit

[24] University of Messina,Department of Medical Oncology

[25] S. Orsola-Malpighi Hospital,Division of Medical Oncology

[26] University Campus Biomedico,Department of Systems Medicine

[27] Sant’Andrea University Hospital,Radiotherapy Department

[28] University La Sapienza,Department of Medical Oncology

[29] Umberto I University Hospital,Scientific Direction

[30] Paolo Giaccone University Hospital,undefined

[31] Pugliese-Ciaccio Hospital,undefined

[32] Medical Oncology Unit,undefined

[33] Belcolle Hospital,undefined

[34] Medical Oncology Unit,undefined

[35] Lanciano-Vasto,undefined

[36] Santa Maria Goretti Hospital,undefined

[37] Fatebenefratelli Hospital,undefined

[38] Medical Oncology AO S. Croce and Carle Teaching Hospital,undefined

[39] University Cattolica del Sacro Cuore,undefined

[40] Department of Medical Oncology,undefined

[41] ASL Nuro,undefined

[42] IRCCS Giovanni Paolo II,undefined

[43] Division of Medical Oncology,undefined

[44] Pescara Hospital,undefined

[45] Research Unit Phase I Trials and Oncology Unit,undefined

[46] ASST,undefined

[47] Reggio Calabria General Hospital,undefined

[48] Medical Oncology,undefined

[49] University Tor Vergata,undefined

[50] IRCCS Regina Elena National Cancer Institute,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 39卷

关键词：

HER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 139 条

[1] Dawood S(2010)Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol 28 92-98
[2] Broglio K(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2 N Engl J Med 344 783-792
[3] Buzdar AU(2005)Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265-4274
[4] Hortobagyi GN(2010)Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care Am J Clin Oncol 33 186-195
[5] Giordano SH(2006)Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733-2743
[6] Slamon DJ(2013)Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a multicenter, double-blind, placebo-controlled, phase 3 study Lancet Oncol 14 461-471
[7] Leyland-Jones B(2012)Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 367 1783-1891
[8] Shak S(2017)Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial Lancet Oncol 18 743-754
[9] Fuchs H(2009)Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models Cancer Res 69 9330-9336
[10] Paton V(2008)Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 68 9280-9290

← 1 2 3 4 5 6 7 8 9 10 →